Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.88 |
| ▸ | USP2 | O75604 | 1/20 | 0.88 |
| ▸ | ATM | Q13315 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639925 | 1.00 | TSHR (0.88) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL7953122 | 0.98 | TSHR (0.85) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL22640122 | 0.98 | TSHR (0.85) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL4579320 | 0.94 | USP2 (1.00) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL13246354 | 0.88 | KDM4E (0.88) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL13246358 | 0.87 | USP2 (0.81) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL12834994 | 0.87 | USP2 (0.81) | TSHRUSP2KDM4EKMT2AMAPT | |
| SCHEMBL6754439 | 0.87 | USP2 (0.81) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL16808057 | 0.87 | TSHR (0.71) | TSHRUSP2ATMCYP2D6CYP2C19 | |
| SCHEMBL16808049 | 0.87 | TSHR (0.71) | TSHRUSP2ATMCYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2298304-A2 | Carboline derivatives useful in the treatment of cancer | PTC Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | RNMT, VEGFA, VHL | TSHR 2566/4885USP2 1985/4885ATM 3586/4885 |
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | TSHR 4656/4885USP2 3312/4885ATM 3431/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | TSHR 2025/4885USP2 4034/4885ATM 4544/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | TSHR 4202/4885USP2 1190/4885ATM 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.